Lineage Cell Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Lineage Cell Therapeutics, Inc. (LCTX) reported Revenue from Contract with Customer, Including Assessed Tax of $943.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $943.00K, a 62.76% decline year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $1.57M, a 24.02% increase year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $6.26M, a 152.74% increase year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $3.54M, a 4.67% increase year-over-year.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $13.61M, a 67.00% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $8.15M, a 7.39% increase from fiscal 2023.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $7.59M, a 43.23% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $13.37M, a 1093.48% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $943.00K 10-Q · filed 2026-08-06 | $2.52M 10-Q · filed 2026-08-06 | $8.78M derived: sum of 3 quarters · filed 2026-08-06 | $12.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.57M 10-Q · filed 2026-05-12 | $7.84M derived: sum of 2 quarters · filed 2026-05-12 | $11.38M derived: sum of 3 quarters · filed 2026-05-12 | $13.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $9.81M derived: sum of 2 quarters · filed 2026-03-05 | $12.34M derived: sum of 3 quarters · filed 2026-08-06 | $13.61M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.54M 10-Q · filed 2025-11-06 | $6.08M derived: sum of 2 quarters · filed 2026-08-06 | $7.35M 10-Q · filed 2025-11-06 | $9.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.53M 10-Q · filed 2026-08-06 | $3.80M 10-Q · filed 2026-08-06 | $6.28M derived: sum of 3 quarters · filed 2026-08-06 | $9.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-12 | $3.75M derived: sum of 2 quarters · filed 2026-05-12 | $7.13M derived: sum of 3 quarters · filed 2026-05-12 | $8.23M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.86M derived: sum of 2 quarters · filed 2026-03-05 | $6.96M derived: sum of 3 quarters · filed 2026-03-05 | $8.15M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.39M 10-Q · filed 2025-11-06 | $4.48M derived: sum of 2 quarters · filed 2025-11-06 | $5.67M 10-Q · filed 2025-11-06 | $7.31M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.10M 10-Q · filed 2025-08-12 | $2.29M 10-Q · filed 2025-08-12 | $3.92M derived: sum of 3 quarters · filed 2025-08-12 | $4.88M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.19M 10-Q · filed 2025-05-13 | $2.83M derived: sum of 2 quarters · filed 2025-05-13 | $3.78M derived: sum of 3 quarters · filed 2025-05-13 | $6.65M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $2.60M derived: sum of 2 quarters · filed 2025-03-10 | $5.47M derived: sum of 3 quarters · filed 2025-03-10 | $7.59M 10-K · filed 2025-03-10 |
| 2023-09-30 | $957.00K 10-Q · filed 2024-11-14 | $3.83M derived: sum of 2 quarters · filed 2024-11-14 | $5.95M 10-Q · filed 2024-11-14 | $7.71M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.87M 10-Q · filed 2024-08-08 | $4.99M 10-Q · filed 2024-08-08 | $6.75M derived: sum of 3 quarters · filed 2024-08-08 | $9.35M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.12M 10-Q · filed 2024-05-09 | $3.88M derived: sum of 2 quarters · filed 2024-05-09 | $6.47M derived: sum of 3 quarters · filed 2024-05-09 | $10.62M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $4.35M derived: sum of 2 quarters · filed 2024-03-07 | $8.50M derived: sum of 3 quarters · filed 2024-03-07 | $13.37M 10-K · filed 2024-03-07 |
| 2022-09-30 | $2.59M 10-Q · filed 2022-11-10 | $6.74M derived: sum of 2 quarters · filed 2023-08-10 | $11.61M 10-Q · filed 2022-11-10 | $12.22M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-06-30 | $4.15M 10-Q · filed 2023-08-10 | $9.01M 10-Q · filed 2023-08-10 | $9.63M derived: sum of 3 quarters · filed 2023-08-10 | $9.92M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $4.87M 10-Q · filed 2023-05-11 | $5.48M derived: sum of 2 quarters · filed 2023-05-11 | $5.77M derived: sum of 3 quarters · filed 2023-05-11 | $5.99M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $614.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $907.00K derived: sum of 2 quarters · filed 2023-03-09 | $1.12M derived: sum of 3 quarters · filed 2023-03-09 | $1.12M 10-K · filed 2023-03-09 |
| 2021-09-30 | $293.00K 10-Q · filed 2022-11-10 | $506.00K derived: sum of 2 quarters · filed 2022-11-10 | $506.00K 10-Q · filed 2022-11-10 | $1.25M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $213.00K 10-Q · filed 2022-08-11 | $213.00K 10-Q · filed 2022-08-11 | $959.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.53M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $391.00K 10-Q · filed 2021-05-13 | $746.00K derived: sum of 2 quarters · filed 2021-05-13 | $1.32M derived: sum of 3 quarters · filed 2021-05-13 | $1.70M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | $355.00K 10-K · filed 2021-03-11 | $926.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.31M derived: sum of 3 quarters · filed 2021-03-11 | $1.83M 10-K · filed 2021-03-11 |
| 2020-09-30 | $571.00K 10-K · filed 2021-03-11 | $957.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.47M 10-Q · filed 2020-11-04 | $2.71M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-06-30 | $386.00K 10-K · filed 2021-03-11 | $900.00K 10-Q · filed 2020-08-06 | $2.14M derived: sum of 3 quarters · filed 2021-05-13 | $2.71M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-03-31 | $514.00K 10-Q · filed 2021-05-13 | $1.75M derived: sum of 2 quarters · filed 2021-05-13 | $2.32M derived: sum of 3 quarters · filed 2021-05-13 | $3.10M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $1.24M 10-K · filed 2021-03-11 | $1.81M derived: sum of 2 quarters · filed 2021-03-11 | $2.59M derived: sum of 3 quarters · filed 2021-03-11 | $3.52M 10-K · filed 2021-03-11 |
| 2019-09-30 | $567.00K 10-K · filed 2021-03-11 | $1.35M derived: sum of 2 quarters · filed 2021-03-11 | $2.27M 10-Q · filed 2020-11-04 | $3.03M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $779.00K 10-K · filed 2021-03-11 | $1.71M 10-Q · filed 2020-08-06 | $2.46M derived: sum of 3 quarters · filed 2021-03-11 | $3.45M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $928.00K 10-K · filed 2021-03-11 | $1.69M derived: sum of 2 quarters · filed 2021-03-11 | $2.67M derived: sum of 3 quarters · filed 2021-03-11 | $5.21M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $758.00K 10-K · filed 2020-03-12 | $1.74M derived: sum of 2 quarters · filed 2020-03-12 | $4.29M derived: sum of 3 quarters · filed 2020-03-12 | $4.99M 10-K · filed 2020-03-12 |
| 2018-09-30 | $982.00K 10-K · filed 2020-03-12 | $3.53M derived: sum of 2 quarters · filed 2020-03-12 | $4.23M 10-Q · filed 2019-11-12 | $5.17M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $2.55M 10-K · filed 2020-03-12 | $3.25M 10-Q · filed 2019-08-08 | $4.19M derived: sum of 3 quarters · filed 2020-03-12 | $5.83M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $701.00K 10-K · filed 2020-03-12 | $1.65M derived: sum of 2 quarters · filed 2020-03-12 | $3.28M derived: sum of 3 quarters · filed 2020-03-12 | $3.66M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $945.00K 10-K · filed 2019-03-14 | $2.58M derived: sum of 2 quarters · filed 2019-03-14 | $2.96M derived: sum of 3 quarters · filed 2019-03-14 | $3.46M 10-K · filed 2019-03-14 |
| 2017-09-30 | $1.64M 10-K · filed 2019-03-14 | $2.01M derived: sum of 2 quarters · filed 2019-03-14 | $2.35M derived: sum of 3 quarters · filed 2019-03-14 | |
| 2017-06-30 | $376.00K 10-K · filed 2019-03-14 | $709.00K derived: sum of 2 quarters · filed 2019-03-14 | ||
| 2017-03-31 | $333.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |